<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; canmab</title>
	<atom:link href="http://www.tapanray.in/tag/canmab/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>‘Herceptin Biosimilars’ Seriously Questioned</title>
		<link>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilars-seriously-questioned</link>
		<comments>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/#comments</comments>
		<pubDate>Fri, 07 Feb 2014 11:17:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CTRI]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hertaz]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[questioned]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[wife]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4969</guid>
		<description><![CDATA[The news struck as an anticlimax, close on the heels of high decibel product launch of ‘Herceptin Biosimilars’ in India, being hyped as the first in the world, bringing much needed relief to many diagnosed breast cancer patients for their &#8230; <a href="http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Herceptin Biosimilar Expands Drug Access to Breast Cancer Patients in India</title>
		<link>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india</link>
		<comments>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/#comments</comments>
		<pubDate>Fri, 24 Jan 2014 13:37:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[herclon]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4908</guid>
		<description><![CDATA[Come February 2014, much to the relief of more than 145,000 patients diagnosed with breast cancer in India, Herceptin of Roche, a critical drug for the treatment of the dreaded disease, will face competition, for the first time, from a &#8230; <a href="http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
